Encyclopedia of Respiratory Medicine, Second Edition, Six Volume Set explores the key processes of lung diseases and their diagnosis and management. The book dissects the molecular and cellular biology, physiology and immunology that underpin normal lung function, along with the aberrations that occur in respiratory diseases, from common disorders such as asthma and COPD to rarer lung diseases such as cystic fibrosis, interstitial lung diseases and pulmonary hypertension. Written in at a time when the globe is in the grip of respiratory pandemic, lung disease has never been so prominent in the public and political conscious.
This new edition will provide new researchers in respiratory medicine with a solid foundation in unfamiliar topics and will update more experienced researchers seeking to step outside their core areas of research to put their work into a broader context.
1. Encyclopaedia Introduction - p. iii 2. Permission Acknowledgments - p. iii 3. List of Illustrations - p. iii 4. List of Tables - p. iii 5. Volume 1 - p. iii 6. Chapter 1: Type I Cells - p. iii 7. Chapter 2: Alveolar Epithelial Type II Cells - p. iii 8. Chapter 3: Endothelial Cells and Endothelium - p. iii 9. Chapter 4: Club Cells - p. iii 10. Chapter 5: Smooth Muscle Cells - p. iii 11. Chapter 6: Fibroblasts - p. iii 12. Chapter 7: Mesothelial Cells - p. iii 13. Chapter 8: Postnatal Lung Epithelial Stem Cells - p. iii 14. Chapter 9: Vasculogenesis, Angiogenesis and Lung Alveolar Development - p. iii 15. Chapter 10: Mucins - p. iii 16. Chapter 11: Mucus - p. iii 17. Chapter 12: Lung Surfactant: Overview - p. iii 18. Chapter 13: Biological Functions of Surfactant Protein A (SP-A) in Health and Disease - p. iii 19. Chapter 14: Surfactant Protein B and C (SP-B and SP-C) - p. iii 20. Chapter 15: Surfactant protein D (SP-D) - p. iii 21. Chapter 16: Integrins - p. iii 22. Chapter 17: Extracellular Matrix: Basement Membranes - p. iii 23. Chapter 18: Matricellular Proteins - p. iii 24. Chapter 19: Extracellular Matrix: Matrix Proteoglycans - p. iii 25. Chapter 20: Extracellular Matrix: Surface Proteoglycans - p. iii 26. Chapter 21: Neural Control of Airway Smooth Muscle - p. iii 27. Chapter 22: Neurophysiology: Neuroanatomy - p. iii 28. Chapter 23: Defense Systems - p. iii 29. Chapter 24: Dendritic cells - p. iii 30. Chapter 25: Pulmonary Macrophages - p. iii 31. Chapter 26: Leukocytes/Neutrophils - p. iii 32. Chapter 27: Eosinophils - p. iii 33. Chapter 28: Leukocytes: Mast Cells and Basophils - p. iii 34. Chapter 29: Leukocytes, Mononuclear Cells: T Cells - p. iii 35. Chapter 30: Erythrocytes - p. iii 36. Chapter 31: Platelets - p. iii 37. Chapter 32: Immunoglobulins - p. iii 38. Chapter 33: Autoantibodies - p. iii 39. Chapter 34: Pathogen Recognition Receptors and the Lung - p. iii 40. Chapter 35: Interferons - p. iii 41. Chapter 36: The Role of the Interleukin 1 Family in Lung Disease - p. iii 42. Chapter 37: Interleukins | IL-4 - p. iii 43. Chapter 38: Interleukin-10 - p. iii 44. Chapter 39: Interleukins | IL-12 - p. iii 45. Chapter 40: Transforming Growth Factor-β (TGF-β) Family of Molecule - p. iii 46. Chapter 41: TNF-α and Pulmonary Diseases - p. iii 47. Chapter 42: Chemokines: An Overview - p. iii 48. Chapter 43: Chemokines: CC Family - p. iii 49. Chapter 44: CXC Chemokine Family - p. iii 50. Chapter 45: Chemokines: XCL1, XCL2 and CX3CL1 - p. iii 51. Chapter 46: Macrophage Migration Inhibitory Factor (MIF) - p. iii 52. Chapter 47: Fibroblast Growth Factor Signaling in Lung Development and Disease - p. iii 53. Chapter 48: Keratinocyte Growth Factor - p. iii 54. Chapter 49: Platelet-Derived Growth Factor - p. iii 55. Chapter 50: Vascular Endothelial Growth Factor and Inflammatory Airway Diseases: An Update - p. iii 56. Chapter 51: Complement - p. iii 57. Chapter 52: Antimicrobial Peptides of the Respiratory Tract - p. iii 58. Chapter 53: Histamine - p. iii 59. Chapter 54: Nitric Oxide and Nitrogen Oxides - p. iii 60. Chapter 55: Lipid Mediators: Overview - p. iii 61. Chapter 56: Lipid Mediators: Leukotrienes - p. iii 62. Chapter 57: Lipid Mediators—Prostanoids - p. iii 63. Chapter 58: Platelet-Activating Factor - p. iii 64. Chapter 59: Lipid Mediators: Lipoxins - p. iii 65. Chapter 60: Coagulation Cascade: Overview - p. iii 66. Chapter 61: Coagulation Cascade: Antithrombin III - p. iii 67. Chapter 62: Coagulation Cascade: Factor V - p. iii 68. Chapter 63: Coagulation Cascade: Factor VII - p. iii 69. Chapter 64: Coagulation Cascde: Factor X - p. iii 70. Chapter 65: Coagulation Cascade: Fibrinogen and Fibrin - p. iii 71. Chapter 66: Coagulation Cascade: Intrinsic Factors - p. iii 72. Chapter 67: Coagulation Cascade: Protein C and Protein S - p. iii 73. Chapter 68: Coagulation Cascade: Thrombin - p. iii 74. Chapter 69: Coagulation Cascade: Tissue Factor - p. iii 75. Chapter 70: Serine Proteinases: Overview - p. iii 76. Chapter 71: Proteinase-Activated Receptors - p. iii 77. Chapter 72: Proteinase Inhibitors: Antichymotrypsin - p. iii 78. Chapter 73: ADAMs and ADAMTSs - p. iii 79. Chapter 74: Aquaporins - p. iii 80. Chapter 75: Chemoreceptor Chapter-the Control of Breathing - p. iii 81. Chapter 76: Arterial Chemoreceptors - p. iii 82. Chapter 77: Pulmonary Collectins - p. iii 83. Chapter 78: Connexins - p. iii 84. Chapter 79: Cytoskeletal Proteins - p. iii 85. Chapter 80: G-Protein-Coupled Receptors - p. iii 86. Chapter 81: Ion Channels: An Overview - p. iii 87. Chapter 82: Ion Transport: Calcium Channels - p. iii 88. Chapter 83: Ion Transport: Chloride Channels - p. iii 89. Chapter 84: Ion Channels: ENaC - p. iii 90. Chapter 85: Ion Transport: Potassium Channels - p. iii 91. Chapter 86: Kallikrein-Kinin Cascade - p. iii 92. Chapter 87: The Use of Keratins as Lung Cell Differentiation Markers and as a Diagnostic Tool in Lung Cancer - p. iii 93. Chapter 88: Kinins and Neuropeptides: Tachykinins - p. iii 94. Chapter 89: Matrix Metalloproteinases - p. iii 95. Chapter 90: Notch - p. iii 96. Chapter 91: Oncostatin M - p. iii 97. Chapter 92: Proteasomes and Ubiquitin - p. iii 98. Chapter 93: Transcription Factors - p. iii 99. Chapter 94: Transcription Factors: Forkhead Box (FOX) - p. iii 100. Chapter 95: Metabolomics - p. iii 101. Chapter 96: Power of Transcriptomics in Lung Biology - p. iii 102. Chapter 97: In Vitro Models to Study Respiratory Biology and Diseases - p. iii 103. Chapter 98: Tracheal Replacement and Tissue Engineered Airways - p. iii 104. Chapter 99: Bioengineering Approaches for the Distal Lung - p. iii 105. Volume 2 - p. iii 106. Chapter 100: History and General Examination - p. iii 107. Chapter 101: Dyspnea - p. iii 108. Chapter 102: Chest Pain - p. iii 109. Chapter 103: Symptoms of Respiratory Disease - p. iii 110. Chapter 104: Hemoptysis - p. iii 111. Chapter 105: Night Sweats - p. iii 112. Chapter 106: Signs of Respiratory Disease: Clubbing and Hypertrophic Osteoarthropathy - p. iii 113. Chapter 107: Signs of Respiratory Disease: Breathing Patterns - p. iii 114. Chapter 108: Signs of Respiratory Disease: Lung Sounds - p. iii 115. Chapter 109: Lung Anatomy and Aging - p. iii 116. Chapter 110: Lymphatic System - p. iii 117. Chapter 111: Pulmonary Circulation - p. iii 118. Chapter 112: Arteries and veins - p. iii 119. Chapter 113: Bronchial Circulation - p. iii 120. Chapter 114: Respiratory Muscles: Chest Wall, Diaphragm and Other Muscles - p. iii 121. Chapter 115: Other Chest Wall Abnormalities - p. iii 122. Chapter 116: Pectus Excavatum and Carinatum - p. iii 123. Chapter 117: Acid-base balance - p. iii 124. Chapter 118: Arterial Blood Gases - p. iii 125. Chapter 119: Carbon Dioxide - p. iii 126. Chapter 120: Diffusion of gases - p. iii 127. Chapter 121: Peripheral gas exchange - p. iii 128. Chapter 122: Permeability of the blood-gas barrier - p. iii 129. Chapter 123: Oxygen-Hemoglobin Dissociation Curve - p. iii 130. Chapter 124: Exercise Physiology - p. iii 131. Chapter 125: Diving - p. iii 132. Chapter 126: High Altitude Physiology and Medicine - p. iii 133. Chapter 127: Alveolar Surface Mechanics - p. iii 134. Chapter 128: Alveolar Wall Micromechanics - p. iii 135. Chapter 129: Stress Distribution in the Lung - p. iii 136. Chapter 130: Dynamics of gas flow and pressure-flow relationships - p. iii 137. Chapter 131: Neurophysiology - p. iii 138. Chapter 132: Reflexes from the lungs and chest wall - p. iii 139. Chapter 133: Asthma—Clinical Features and Diagnosis - p. iii 140. Chapter 134: Acute Asthma - p. iii 141. Chapter 135: Pathology of Asthma - p. iii 142. Chapter 136: Genetics of Asthma: Insights From Genome Wide Association Studies - p. iii 143. Chapter 137: Epigenetics of Asthma - p. iii 144. Chapter 138: Inflammatory Mechanisms in Asthma - p. iii 145. Chapter 139: Biomarkers in Asthma - p. iii 146. Chapter 140: Airway Smooth Muscle Dysfunction in Asthma - p. iii 147. Chapter 141: Asthma: NSAID Exacerbated Respiratory Disease (NERD) Formerly Aspirin-Intolerant Asthma - p. iii 148. Chapter 142: Asthma in Pregnancy - p. iii 149. Chapter 143: Adult Severe Asthma - p. iii 150. Chapter 144: Current Management of Asthma - p. iii 151. Chapter 145: Biological Therapies for Asthma - p. iii 152. Chapter 146: Mechanisms of Allergy - p. iii 153. Chapter 147: Allergic Rhinitis - p. iii 154. Chapter 148: Allergic Bronchopulmonary Aspergillosis - p. iii 155. Chapter 149: Current Drug Treatments for Allergy - p. iii 156. Chapter 150: Immunotherapy for Allergy - p. iii 157. Chapter 151: COPD Genetics - p. iii 158. Chapter 152: COPD Epidemiology - p. iii 159. Chapter 153: Epigenetics in COPD: An Epidemiological Point of View - p. iii 160. Chapter 154: Pathology of Chronic Obstructive Pulmonary Disease - p. iii 161. Chapter 155: Inflammatory and Immune Mechanisms in COPD - p. iii 162. Chapter 156: Biomarkers in COPD - p. iii 163. Chapter 157: Bacterial Colonization in COPD - p. iii 164. Chapter 158: Accelerated Lung Aging and Cellular Senescence in COPD - p. iii 165. Chapter 159: Mucus Hypersecretion, Hyperconcentration and Chronic Bronchitis - p. iii 166. Chapter 160: Trajectories of COPD - p. iii 167. Chapter 161: Clinical Features and Diagnosis of COPD - p. iii 168. Chapter 162: Overview of Current Management of COPD - p. iii 169. Chapter 163: Oxygen Therapy in COPD - p. iii 170. Chapter 164: Pulmonary Rehabilitation for COPD - p. iii 171. Chapter 165: Comorbidities in Patients With Chronic Obstructive Pulmonary Disease - p. iii 172. Chapter 166: Alpha 1 Antitrypsin - p. iii 173. Chapter 167: COPD in Never Smokers - p. iii 174. Chapter 168: Asthma—COPD Overlap - p. iii 175. Chapter 169: Bronchodilators for Airway Disease - p. iii 176. Chapter 170: Other Drugs for Asthma and COPD - p. iii 177. Chapter 171: New Drugs for Airway Diseases - p. iii 178. Chapter 172: Inhaler Devices - p. iii 179. Volume 3 - p. iii 180. Chapter 173: General Principles of ILD: Diagnosis and Management - p. iii 181. Chapter 174: The Physiology of Interstitial Lung Disease - p. iii 182. Chapter 175: Overview on Radiologic Patterns in Interstitial Lung Disease - p. iii 183. Chapter 176: Overview of the Histologic Patterns in Interstitial Lung Disease - p. iii 184. Chapter 177: The Role of Bronchoscopy in Interstitial Lung Disease - p. iii 185. Chapter 178: Comprehensive Care of Interstitial Lung Disease - p. iii 186. Chapter 179: Common Co-Morbidities in Fibrosing Interstitial Lung Disease - p. iii 187. Chapter 180: Interstitial Lung Abnormalities and Early Interstitial Lung Disease - p. iii 188. Chapter 181: The Genetics of Interstitial Lung Diseases - p. iii 189. Chapter 182: Interaction Between Epithelial and Mesenchymal Cells in Interstitial Lung Disease - p. iii 190. Chapter 183: The Extracellular Matrix-Cell Interaction in ILD - p. iii 191. Chapter 184: The Role of the Innate Immune System in Interstitial Lung Disease - p. iii 192. Chapter 185: Adaptive Immunity in Interstitial Lung Disease - p. iii 193. Chapter 186: Stem Cells and Progenitor Cells in Interstitial Lung Disease - p. iii 194. Chapter 187: Animal Models of Fibrotic Interstitial Lung Disease - p. iii 195. Chapter 188: Novel Approaches to Drug Discovery in Interstitial Lung Disease - p. iii 196. Chapter 189: Epidemiology and Diagnosis of Idiopathic Pulmonary Fibrosis - p. iii 197. Chapter 190: Acute Exacerbation of Idiopathic Pulmonary Fibrosis - p. iii 198. Chapter 191: Idiopathic Pulmonary Fibrosis-Treatment and Management - p. iii 199. Chapter 192: Organizing Pneumonia - p. iii 200. Chapter 193: Smoking-Related—Interstitial Lung Disease - p. iii 201. Chapter 194: Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease - p. iii 202. Chapter 195: Hypersensitivity Pneumonitis - p. iii 203. Chapter 196: Connective Tissue Diseases-Associated Interstitial Lung Disease: A Focused Study on Sjogren’s Syndrome, Mixed Connective Tissue Disease, and Systemic Lupus Erythematosus - p. iii 204. Chapter 197: Interstitial Pneumonia With Autoimmune Features - p. iii 205. Chapter 198: Rheumatoid Arthritis Interstitial Lung Disease - p. iii 206. Chapter 199: Scleroderma Associated Interstitial Lung Disease - p. iii 207. Chapter 200: Myositis-Associated Interstitial Lung Disease - p. iii 208. Chapter 201: Vasculitis and Alveolar Hemorrhage - p. iii 209. Chapter 202: Drug Toxicity and Interstitial Lung Disease - p. iii 210. Chapter 203: Occupational Interstitial Lung Disease - p. iii 211. Chapter 204: Sarcoidosis - p. iii 212. Chapter 205: Eosinophilic Interstitial Pneumonia - p. iii 213. Chapter 206: Lymphangioleiomyomatosis - p. iii 214. Chapter 207: Pulmonary Alveolar Proteinosis - p. iii 215. Chapter 208: Miscellaneous Interstitial Lung Diseases - p. iii 216. Chapter 209: Physiology of the Normal Pulmonary Circulation - p. iii 217. Chapter 210: Physiology of the Normal Right Ventricle - p. iii 218. Chapter 211: Pathology of Pulmonary Arterial Hypertension - p. iii 219. Chapter 212: Pathobiology of Pulmonary Hypertension - p. iii 220. Chapter 213: Pathobiology of Right Ventricular Failure - p. iii 221. Chapter 214: Clinical Features of Pulmonary Hypertension and Right Heart Failure - p. iii 222. Chapter 215: Classification of Pulmonary Vascular Disease - p. iii 223. Chapter 216: Imaging of the Heart and the Pulmonary Circulation in Pulmonary Hypertension - p. iii 224. Chapter 217: Cardiopulmonary Exercise Testing in Pulmonary Vascular Disease - p. iii 225. Chapter 218: Biomarkers in Pulmonary Hypertension - p. iii 226. Chapter 219: Cardiac Catheterization in Pulmonary Hypertension - p. iii 227. Chapter 220: Group 1 Clinical Features and Treatment - p. iii 228. Chapter 221: Exercise Training in Pulmonary Hypertension - p. iii 229. Chapter 222: Lung Transplantation for Pulmonary Arterial Hypertension: Recent Developments—Donor Organ Preservation, Bio-Artificial Lung and Xenotransplantation - p. iii 230. Chapter 223: Group 2 Pulmonary Hypertension: Clinical Features and Treatment - p. iii 231. Chapter 224: Group 3 PH: Clinical Features and Treatment - p. iii 232. Chapter 225: Group 4 PH—Chronic Thromboembolic Pulmonary Hypertension - p. iii 233. Chapter 226: Acute Pulmonary Embolism - p. iii 234. Chapter 227: Diseases Associated with Group 5 Pulmonary Hypertension - p. iii 235. Chapter 228: Pulmonary Hypertension in Children: A Global View - p. iii 236. Chapter 229: The Pulmonary Circulation and the Right Ventricle in ARDS - p. iii 237. Chapter 230: Hepatopulmonary Syndrome - p. iii 238. Chapter 231: Pulmonary Arteriovenous Malformations - p. iii 239. Volume 4 - p. iii 240. Chapter 232: Streptococcus pneumoniae - p. iii 241. Chapter 233: Pseudomonas aeruginosa - p. iii 242. Chapter 234: Mycoplasma and Chlamydophila - p. iii 243. Chapter 235: Legionella pneumophila - p. iii 244. Chapter 236: Aspergillus Lung Disease - p. iii 245. Chapter 237: Pneumocystis - p. iii 246. Chapter 238: Tuberculosis - p. iii 247. Chapter 239: Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) - p. iii 248. Chapter 240: Other Bacterial and Fungal Respiratory Bacterial Pathogens - p. iii 249. Chapter 241: Respiratory Viral Pathogens - p. iii 250. Chapter 242: Human Immunodeficiency Virus - p. iii 251. Chapter 243: Human Coronavirus Infections—Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and SARS-CoV-2 - p. iii 252. Chapter 244: Parasitic Infections of the Lung - p. iii 253. Chapter 245: The Respiratory Microbiome in Health and Disease - p. iii 254. Chapter 246: Pneumonia—Overview - p. iii 255. Chapter 247: Community-Acquired Pneumonia - p. iii 256. Chapter 248: Hospital-Acquired and Ventilator-Associated Pneumonia - p. iii 257. Chapter 249: Pneumonia in the Immunocompromised Host - p. iii 258. Chapter 250: Severe Acute Respiratory Syndrome Coronavirus 2 - p. iii 259. Chapter 251: Pleural Infection - p. iii 260. Chapter 252: Infective Exacerbations of Chronic Lung Disease - p. iii 261. Chapter 253: Bronchiectasis - p. iii 262. Chapter 254: Long Term Complications of Tuberculosis and Pneumonia - p. iii 263. Chapter 255: Antibiotic Therapy for Respiratory Infection - p. iii 264. Chapter 256: Environmental Influences on Respiratory Infection - p. iii 265. Chapter 257: Pleural Disease: Overview - p. iii 266. Chapter 258: Anatomy and Physiology of the Pleural Space - p. iii 267. Chapter 259: Imaging of the Pleura: Ultrasound - p. iii 268. Chapter 260: Imaging of the Pleura: CT, MRI and PET - p. iii 269. Chapter 261: Pleural Effusions: Overview and Diagnostic Approach - p. iii 270. Chapter 262: Pleural Effusion: Infection (Para-Pneumonic and Empyema) - p. iii 271. Chapter 263: Pleural Effusion: Malignancy - p. iii 272. Chapter 264: Pleural Effusion: Chylous Effusions - p. iii 273. Chapter 265: Eosinophilic Pleural Effusions - p. iii 274. Chapter 266: Pleural Effusion: Tuberculous Effusion - p. iii 275. Chapter 267: Pleural Effusion: Hepatic Hydrothorax - p. iii 276. Chapter 268: Pleural Effusion: Hemothorax - p. iii 277. Chapter 269: Pleural Effusions: Post-Surgical and Post-Cardiac Injury - p. iii 278. Chapter 270: Spontaneous Pneumothorax - p. iii 279. Chapter 271: Traumatic Pneumothorax - p. iii 280. Chapter 272: Pneumomediastinum - p. iii 281. Chapter 273: Bronchopleural Fistula Following Anatomical Lung Resection - p. iii 282. Chapter 274: Unexpandable Lung - p. iii 283. Chapter 275: Benign Pleural Thickening, Fibrosis and Plaques - p. iii 284. Chapter 276: Malignant Pleural Mesothelioma - p. iii 285. Chapter 277: Rare Pleural Diseases - p. iii 286. Chapter 278: Pleural Interventions - Thoracentesis - p. iii 287. Chapter 279: Pleural Interventions - Chest Drain Insertion - p. iii 288. Chapter 280: Pleural Interventions: Manometry - p. iii 289. Chapter 281: Pleural Interventions: Closed Pleural Biopsy - p. iii 290. Chapter 282: Pleural Interventions—Thoracoscopy - p. iii 291. Chapter 283: Pleurodesis - p. iii 292. Chapter 284: Indwelling Pleural Catheters - p. iii 293. Chapter 285: Overview of Lung Cancer - p. iii 294. Chapter 286: Lung Cancer Screening - p. iii 295. Chapter 287: Behavioral Science Behind Lung Cancer Screening - p. iii 296. Chapter 288: Epidemiology of Lung Cancer - p. iii 297. Chapter 289: Tobacco Dependency - p. iii 298. Chapter 290: Pulmonary Nodules - p. iii 299. Chapter 291: Preinvasive Airway Lesions - p. iii 300. Chapter 292: Clinical Presentation and Diagnostic Approach in Suspected Lung Cancer - p. iii 301. Chapter 293: The Role of a Lung CNS - p. iii 302. Chapter 294: Imaging Techniques in Lung Cancer - p. iii 303. Chapter 295: Differential Diagnosis of Mediastinal Masses - p. iii 304. Chapter 296: Endobronchial Ultrasound for Mediastinal Staging in Lung Cancer - p. iii 305. Chapter 297: Interventional Bronchoscopy - p. iii 306. Chapter 298: Pathology of Lung Cancer - p. iii 307. Chapter 299: Metastases From Lung Cancer - p. iii 308. Chapter 300: Management of Local Disease in NSCLC - p. iii 309. Chapter 301: Management of Locally Advanced Non-Small Cell Lung Cancer - p. iii 310. Volume 5 - p. iii 311. Chapter 302: Management of Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC) - p. iii 312. Chapter 303: Molecular Targetable Pathways – EGFR - p. iii 313. Chapter 304: Molecular Targetable Pathways—ALK - p. iii 314. Chapter 305: Molecular Targetable Pathways and Therapy—ROS1 - p. iii 315. Chapter 306: KRAS: The Art of Understanding a Complex Gene - p. iii 316. Chapter 307: Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras) - p. iii 317. Chapter 308: Current Role of Immunotherapy - p. iii 318. Chapter 309: Management of Advanced Disease in NSCLC - p. iii 319. Chapter 310: Symptomatic and Supportive Care - p. iii 320. Chapter 311: Pulmonary Complications of Lung Cancer Therapies - p. iii 321. Chapter 312: Small Cell Lung Cancer - p. iii 322. Chapter 313: Introduction and terminology of sleep disordered breathing - p. iii 323. Chapter 314: Physiology of Sleep From Infancy to Old Age - p. iii 324. Chapter 315: Obstructive Sleep Apnea Phenotyping to Understand Pathophysiology and Improve Treatment and Outcomes - p. iii 325. Chapter 316: Vascular Consequences of Obstructive Sleep Apnea - p. iii 326. Chapter 317: Metabolic Consequences of Obstructive Sleep Apnea - p. iii 327. Chapter 318: Cognitive and Neurologic Aspects of Obstructive Sleep Apnea - p. iii 328. Chapter 319: Clinical Assessment of the Patient With Respiratory Sleep Disorder - p. iii 329. Chapter 320: Role of Screening in Sleep Disordered Breathing (SDB) - p. iii 330. Chapter 321: Respiratory Polygraphy - p. iii 331. Chapter 322: Use of Polysomnography - p. iii 332. Chapter 323: Weight Loss and Positional Management in OSA - p. iii 333. Chapter 324: Positive Pressure Therapy in OSA - p. iii 334. Chapter 325: Role of Mandibular Advancement Splints and Dental Devices in OSA - p. iii 335. Chapter 326: ENT Management of Obstructive Sleep Apnea - p. iii 336. Chapter 327: Surgical and Anesthetic Assessment in Patients With SDB - p. iii 337. Chapter 328: Comorbidities and Their Impact on Sleep Disordered Breathing - p. iii 338. Chapter 329: Impact of Intrinsic Sleep Disorders on Sleep Disordered Breathing - p. iii 339. Chapter 330: Pathophysiology of Central Sleep Apnea and Complex Sleep Apnea Syndromes - p. iii 340. Chapter 331: Positive Airway Pressure Therapies in Central Sleep Apnea - p. iii 341. Chapter 332: Management of Complex Sleep Apnea Syndromes (Including Treatment Emergent and Treatment Persistent Central Sleep Apnea) - p. iii 342. Chapter 333: Pathophysiology of Obesity Hypoventilation Syndrome - p. iii 343. Chapter 334: Management of Obesity Hypoventilation Syndrome - p. iii 344. Chapter 335: Pathophysiology of Hypoventilation in Neurological, Neuromuscular and Chest Wall Disease - p. iii 345. Chapter 336: NIV in Ventilatory Failure Due to Neuromuscular and Chest Wall Disorders - p. iii 346. Chapter 337: Non-Invasive Ventilation in Acute, Post-Acute and Stable COPD - p. iii 347. Chapter 338: Medico Legal and Economic Aspects of OSA - p. iii 348. Chapter 339: Acute Respiratory Distress Syndrome - p. iii 349. Chapter 340: ARDS in Patients Without Risk Factors - p. iii 350. Chapter 341: Pulmonary Embolism Causing Severe Organ Failure - p. iii 351. Chapter 342: Life Threatening Asthma - p. iii 352. Chapter 343: Life Threatening Chronic Obstructive Pulmonary Disease (COPD) - p. iii 353. Chapter 344: Management of Acute on Chronic Respiratory Failure Associated With Interstitial Lung Disease - p. iii 354. Chapter 345: Severe Community-Acquired Pneumonia - p. iii 355. Chapter 346: Severe Hospital-Acquired Pneumonia - p. iii 356. Chapter 347: Management of Coronavirus Disease 2019 (COVID-19) Pneumonia - p. iii 357. Chapter 348: Challenges in Severe Influenza Pneumonia - p. iii 358. Chapter 349: Severe Middle East Respiratory Syndrome (MERS) Pneumonia - p. iii 359. Chapter 350: Herpesviruses in Critically Ill Patients With ARDS - p. iii 360. Chapter 351: Perioperative Management of Lung Transplant Recipients - p. iii 361. Chapter 352: Ventilator-Associated Lung Injury - p. iii 362. Chapter 353: Right-Ventricle Protective Ventilation - p. iii 363. Chapter 354: Optimizing Mechanical Ventilation in Refractory ARDS - p. iii 364. Chapter 355: Tracheostomy - p. iii 365. Chapter 356: When To Do a Tracheostomy? - p. iii 366. Chapter 357: Weaning From Mechanical Ventilation - p. iii 367. Chapter 358: Mechanical Ventilation in 2035: Indications, Monitoring and Outcomes - p. iii 368. Chapter 359: Optimizing Sedation in Patients Receiving Mechanical Ventilation - p. iii 369. Chapter 360: Dyspnea in Patients Receiving Mechanical Ventilation - p. iii 370. Chapter 361: ECLS: What Every Clinician Should Know - p. iii 371. Chapter 362: Cognitive Dysfunction in ARDS Survivors - p. iii 372. Chapter 363: Ventilator-Associated Events: Definitions and Uses - p. iii 373. Chapter 364: Ventilator-Associated Tracheobronchitis - p. iii 374. Chapter 365: Airways and Ventilation Management During CPR - p. iii 375. Chapter 366: The Obese Patient With Acute Respiratory Failure - p. iii 376. Chapter 367: Results of Mechanical Ventilation in Cancer Patients - p. iii 377. Chapter 368: Delirium in the Intensive Care Unit - p. iii 378. Chapter 369: Echocardiography of the Ventilated Patient - p. iii 379. Chapter 370: Donor Selection and Management - p. iii 380. Chapter 371: Organ Allocation - p. iii 381. Chapter 372: Lung Transplantation: Recipient Selection - p. iii 382. Chapter 373: Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant - p. iii 383. Chapter 374: Surgical Advances in Lung Transplantation - p. iii 384. Chapter 375: Lung Transplantation for Cystic Fibrosis - p. iii 385. Chapter 376: Lung Transplantation for Pulmonary Hypertension - p. iii 386. Chapter 377: A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis - p. iii 387. Chapter 378: Lung Transplantation for Chronic Obstructive Pulmonary Disease - p. iii 388. Chapter 379: Immunosuppression - p. iii 389. Chapter 380: Opportunistic Bacterial, Fungal and Viral Infections in Lung Transplantation - p. iii 390. Chapter 381: Lung Transplant Primary Graft Dysfunction - p. iii 391. Chapter 382: Acute Cellular Rejection - p. iii 392. Chapter 383: Antibody-Mediated Rejection After Lung Transplantation - p. iii 393. Chapter 384: Chronic Lung Allograft Dysfunction - p. iii 394. Chapter 385: Airway Complications After Lung Transplantation - p. iii 395. Chapter 386: Malignancy Following Lung Transplantation - p. iii 396. Chapter 387: Patient-Centered Outcomes in Lung Transplantation - p. iii 397. Volume 6 - p. iii 398. Chapter 388: Normal Lung Development in Relation to Clinical Practice and the Impact of Environment on Development - p. iii 399. Chapter 389: Structural Abnormalities at Birth (Haemangioma, TOF, Airway Malacia, CPM) - p. iii 400. Chapter 390: Prematurity and Intrauterine Insults - p. iii 401. Chapter 391: Measuring Respiratory Function - p. iii 402. Chapter 392: Imaging of the Lung in Childhood - p. iii 403. Chapter 393: Pathology of the Lung Through Childhood - p. iii 404. Chapter 394: Disorders of Respiratory Control in Childhood - p. iii 405. Chapter 395: Early Life Respiratory Infection - p. iii 406. Chapter 396: Community-Acquired Pneumonia in Childhood - p. iii 407. Chapter 397: Pleural Effusion, Necrotizing Pneumonia and Long-Term Morbidity of Respiratory Infection in Childhood - p. iii 408. Chapter 398: Cystic Fibrosis—Diagnosis, Genetics and Lifelong Effects - p. iii 409. Chapter 399: Cystic Fibrosis Cellular Treatments - p. iii 410. Chapter 400: Cystic Fibrosis Therapies - p. iii 411. Chapter 401: Primary Ciliary Dyskinesia - p. iii 412. Chapter 402: Bronchiectasis in Childhood (Including PBB) - p. iii 413. Chapter 403: Diffuse Parenchymal Lung Disease in Early Childhood - p. iii 414. Chapter 404: Diffuse Parenchymal Lung Disease in Later Childhood - p. iii 415. Chapter 405: Recurrent Wheeze of Early Childhood - p. iii 416. Chapter 406: Diagnosing, Monitoring and Treating Asthma - p. iii 417. Chapter 407: Severe Asthma in Children and Young People - p. iii 418. Chapter 408: Cardiac - Pulmonary Hypertension, Gastro-Intestinal (GOR, Hepatopulmonary Syndrome), Hematology/Oncology (Infections, Approach to Diagnosis), Neuromuscular (Bulbar, Diaphragm, Intercostal, Spinal) - p. iii 419. Chapter 409: Oxygen Therapy in Children - p. iii 420. Chapter 410: Long Term Ventilation in Children - p. iii 421. Chapter 411: Lung Transplantation in Children - p. iii 422. Chapter 412: Epidemiological Study Design - p. iii 423. Chapter 413: Indoor Environmental Allergens - p. iii 424. Chapter 414: Household Air Pollution and Associated Health Effects in Low and Middle Income Countries - p. iii 425. Chapter 415: Indoor Air Pollution in Industrialized Countries - p. iii 426. Chapter 416: Outdoor Allergens: Pollens and Molds and Their Relationship to Climate Changes - p. iii 427. Chapter 417: Air Pollutants Short-Term and Long Term Effects - p. iii 428. Chapter 418: Acute Inhalational Injury - p. iii 429. Chapter 419: Epidemiological Study of Respiratory Diseases Among Dust Exposed Workers - p. iii 430. Chapter 420: Desert Dust - p. iii 431. Chapter 421: Heavy Metals - p. iii 432. Chapter 422: Work-Related Asthma - p. iii 433. Chapter 423: COPD - p. iii 434. Chapter 424: Air Pollution in Interstitial Lung Diseases and Associated Autoimmune Diseases - p. iii 435. Chapter 425: Environment and Mesothelioma - p. iii 436. Chapter 426: Environmental Mycobacteria - p. iii 437. Chapter 427: Occupational and Environmental Tuberculosis - p. iii 438. Chapter 428: Respiratory Diseases in Farmers - p. iii 439. Chapter 429: Respiratory Health in Migrants and Refugees - p. iii 440. Chapter 430: Unraveling the Exposome in Direct and Indirect Respiratory Effects of Climate Change - p. iii 441. Chapter 431: Thunderstorm—Asthma: Thunderstorm and Asthma in Allergic-Atopic Subjects - p. iii 442. Index - p. iii 443. Authors - p. iii
Encyclopedia of Respiratory Medicine, Second Edition, Six Volume Set explores the key processes of lung diseases and their diagnosis and management. The book dissects the molecular and cellular biology, physiology and immunology that underpin normal lung function, along with the aberrations that occur in respiratory diseases, from common disorders such as asthma and COPD to rarer lung diseases such as cystic fibrosis, interstitial lung diseases and pulmonary hypertension. Written in at a time when the globe is in the grip of respiratory pandemic, lung disease has never been so prominent in the public and political conscious.
This new edition will provide new researchers in respiratory medicine with a solid foundation in unfamiliar topics and will update more experienced researchers seeking to step outside their core areas of research to put their work into a broader context.
1. Encyclopaedia Introduction - p. iii 2. Permission Acknowledgments - p. iii 3. List of Illustrations - p. iii 4. List of Tables - p. iii 5. Volume 1 - p. iii 6. Chapter 1: Type I Cells - p. iii 7. Chapter 2: Alveolar Epithelial Type II Cells - p. iii 8. Chapter 3: Endothelial Cells and Endothelium - p. iii 9. Chapter 4: Club Cells - p. iii 10. Chapter 5: Smooth Muscle Cells - p. iii 11. Chapter 6: Fibroblasts - p. iii 12. Chapter 7: Mesothelial Cells - p. iii 13. Chapter 8: Postnatal Lung Epithelial Stem Cells - p. iii 14. Chapter 9: Vasculogenesis, Angiogenesis and Lung Alveolar Development - p. iii 15. Chapter 10: Mucins - p. iii 16. Chapter 11: Mucus - p. iii 17. Chapter 12: Lung Surfactant: Overview - p. iii 18. Chapter 13: Biological Functions of Surfactant Protein A (SP-A) in Health and Disease - p. iii 19. Chapter 14: Surfactant Protein B and C (SP-B and SP-C) - p. iii 20. Chapter 15: Surfactant protein D (SP-D) - p. iii 21. Chapter 16: Integrins - p. iii 22. Chapter 17: Extracellular Matrix: Basement Membranes - p. iii 23. Chapter 18: Matricellular Proteins - p. iii 24. Chapter 19: Extracellular Matrix: Matrix Proteoglycans - p. iii 25. Chapter 20: Extracellular Matrix: Surface Proteoglycans - p. iii 26. Chapter 21: Neural Control of Airway Smooth Muscle - p. iii 27. Chapter 22: Neurophysiology: Neuroanatomy - p. iii 28. Chapter 23: Defense Systems - p. iii 29. Chapter 24: Dendritic cells - p. iii 30. Chapter 25: Pulmonary Macrophages - p. iii 31. Chapter 26: Leukocytes/Neutrophils - p. iii 32. Chapter 27: Eosinophils - p. iii 33. Chapter 28: Leukocytes: Mast Cells and Basophils - p. iii 34. Chapter 29: Leukocytes, Mononuclear Cells: T Cells - p. iii 35. Chapter 30: Erythrocytes - p. iii 36. Chapter 31: Platelets - p. iii 37. Chapter 32: Immunoglobulins - p. iii 38. Chapter 33: Autoantibodies - p. iii 39. Chapter 34: Pathogen Recognition Receptors and the Lung - p. iii 40. Chapter 35: Interferons - p. iii 41. Chapter 36: The Role of the Interleukin 1 Family in Lung Disease - p. iii 42. Chapter 37: Interleukins | IL-4 - p. iii 43. Chapter 38: Interleukin-10 - p. iii 44. Chapter 39: Interleukins | IL-12 - p. iii 45. Chapter 40: Transforming Growth Factor-β (TGF-β) Family of Molecule - p. iii 46. Chapter 41: TNF-α and Pulmonary Diseases - p. iii 47. Chapter 42: Chemokines: An Overview - p. iii 48. Chapter 43: Chemokines: CC Family - p. iii 49. Chapter 44: CXC Chemokine Family - p. iii 50. Chapter 45: Chemokines: XCL1, XCL2 and CX3CL1 - p. iii 51. Chapter 46: Macrophage Migration Inhibitory Factor (MIF) - p. iii 52. Chapter 47: Fibroblast Growth Factor Signaling in Lung Development and Disease - p. iii 53. Chapter 48: Keratinocyte Growth Factor - p. iii 54. Chapter 49: Platelet-Derived Growth Factor - p. iii 55. Chapter 50: Vascular Endothelial Growth Factor and Inflammatory Airway Diseases: An Update - p. iii 56. Chapter 51: Complement - p. iii 57. Chapter 52: Antimicrobial Peptides of the Respiratory Tract - p. iii 58. Chapter 53: Histamine - p. iii 59. Chapter 54: Nitric Oxide and Nitrogen Oxides - p. iii 60. Chapter 55: Lipid Mediators: Overview - p. iii 61. Chapter 56: Lipid Mediators: Leukotrienes - p. iii 62. Chapter 57: Lipid Mediators—Prostanoids - p. iii 63. Chapter 58: Platelet-Activating Factor - p. iii 64. Chapter 59: Lipid Mediators: Lipoxins - p. iii 65. Chapter 60: Coagulation Cascade: Overview - p. iii 66. Chapter 61: Coagulation Cascade: Antithrombin III - p. iii 67. Chapter 62: Coagulation Cascade: Factor V - p. iii 68. Chapter 63: Coagulation Cascade: Factor VII - p. iii 69. Chapter 64: Coagulation Cascde: Factor X - p. iii 70. Chapter 65: Coagulation Cascade: Fibrinogen and Fibrin - p. iii 71. Chapter 66: Coagulation Cascade: Intrinsic Factors - p. iii 72. Chapter 67: Coagulation Cascade: Protein C and Protein S - p. iii 73. Chapter 68: Coagulation Cascade: Thrombin - p. iii 74. Chapter 69: Coagulation Cascade: Tissue Factor - p. iii 75. Chapter 70: Serine Proteinases: Overview - p. iii 76. Chapter 71: Proteinase-Activated Receptors - p. iii 77. Chapter 72: Proteinase Inhibitors: Antichymotrypsin - p. iii 78. Chapter 73: ADAMs and ADAMTSs - p. iii 79. Chapter 74: Aquaporins - p. iii 80. Chapter 75: Chemoreceptor Chapter-the Control of Breathing - p. iii 81. Chapter 76: Arterial Chemoreceptors - p. iii 82. Chapter 77: Pulmonary Collectins - p. iii 83. Chapter 78: Connexins - p. iii 84. Chapter 79: Cytoskeletal Proteins - p. iii 85. Chapter 80: G-Protein-Coupled Receptors - p. iii 86. Chapter 81: Ion Channels: An Overview - p. iii 87. Chapter 82: Ion Transport: Calcium Channels - p. iii 88. Chapter 83: Ion Transport: Chloride Channels - p. iii 89. Chapter 84: Ion Channels: ENaC - p. iii 90. Chapter 85: Ion Transport: Potassium Channels - p. iii 91. Chapter 86: Kallikrein-Kinin Cascade - p. iii 92. Chapter 87: The Use of Keratins as Lung Cell Differentiation Markers and as a Diagnostic Tool in Lung Cancer - p. iii 93. Chapter 88: Kinins and Neuropeptides: Tachykinins - p. iii 94. Chapter 89: Matrix Metalloproteinases - p. iii 95. Chapter 90: Notch - p. iii 96. Chapter 91: Oncostatin M - p. iii 97. Chapter 92: Proteasomes and Ubiquitin - p. iii 98. Chapter 93: Transcription Factors - p. iii 99. Chapter 94: Transcription Factors: Forkhead Box (FOX) - p. iii 100. Chapter 95: Metabolomics - p. iii 101. Chapter 96: Power of Transcriptomics in Lung Biology - p. iii 102. Chapter 97: In Vitro Models to Study Respiratory Biology and Diseases - p. iii 103. Chapter 98: Tracheal Replacement and Tissue Engineered Airways - p. iii 104. Chapter 99: Bioengineering Approaches for the Distal Lung - p. iii 105. Volume 2 - p. iii 106. Chapter 100: History and General Examination - p. iii 107. Chapter 101: Dyspnea - p. iii 108. Chapter 102: Chest Pain - p. iii 109. Chapter 103: Symptoms of Respiratory Disease - p. iii 110. Chapter 104: Hemoptysis - p. iii 111. Chapter 105: Night Sweats - p. iii 112. Chapter 106: Signs of Respiratory Disease: Clubbing and Hypertrophic Osteoarthropathy - p. iii 113. Chapter 107: Signs of Respiratory Disease: Breathing Patterns - p. iii 114. Chapter 108: Signs of Respiratory Disease: Lung Sounds - p. iii 115. Chapter 109: Lung Anatomy and Aging - p. iii 116. Chapter 110: Lymphatic System - p. iii 117. Chapter 111: Pulmonary Circulation - p. iii 118. Chapter 112: Arteries and veins - p. iii 119. Chapter 113: Bronchial Circulation - p. iii 120. Chapter 114: Respiratory Muscles: Chest Wall, Diaphragm and Other Muscles - p. iii 121. Chapter 115: Other Chest Wall Abnormalities - p. iii 122. Chapter 116: Pectus Excavatum and Carinatum - p. iii 123. Chapter 117: Acid-base balance - p. iii 124. Chapter 118: Arterial Blood Gases - p. iii 125. Chapter 119: Carbon Dioxide - p. iii 126. Chapter 120: Diffusion of gases - p. iii 127. Chapter 121: Peripheral gas exchange - p. iii 128. Chapter 122: Permeability of the blood-gas barrier - p. iii 129. Chapter 123: Oxygen-Hemoglobin Dissociation Curve - p. iii 130. Chapter 124: Exercise Physiology - p. iii 131. Chapter 125: Diving - p. iii 132. Chapter 126: High Altitude Physiology and Medicine - p. iii 133. Chapter 127: Alveolar Surface Mechanics - p. iii 134. Chapter 128: Alveolar Wall Micromechanics - p. iii 135. Chapter 129: Stress Distribution in the Lung - p. iii 136. Chapter 130: Dynamics of gas flow and pressure-flow relationships - p. iii 137. Chapter 131: Neurophysiology - p. iii 138. Chapter 132: Reflexes from the lungs and chest wall - p. iii 139. Chapter 133: Asthma—Clinical Features and Diagnosis - p. iii 140. Chapter 134: Acute Asthma - p. iii 141. Chapter 135: Pathology of Asthma - p. iii 142. Chapter 136: Genetics of Asthma: Insights From Genome Wide Association Studies - p. iii 143. Chapter 137: Epigenetics of Asthma - p. iii 144. Chapter 138: Inflammatory Mechanisms in Asthma - p. iii 145. Chapter 139: Biomarkers in Asthma - p. iii 146. Chapter 140: Airway Smooth Muscle Dysfunction in Asthma - p. iii 147. Chapter 141: Asthma: NSAID Exacerbated Respiratory Disease (NERD) Formerly Aspirin-Intolerant Asthma - p. iii 148. Chapter 142: Asthma in Pregnancy - p. iii 149. Chapter 143: Adult Severe Asthma - p. iii 150. Chapter 144: Current Management of Asthma - p. iii 151. Chapter 145: Biological Therapies for Asthma - p. iii 152. Chapter 146: Mechanisms of Allergy - p. iii 153. Chapter 147: Allergic Rhinitis - p. iii 154. Chapter 148: Allergic Bronchopulmonary Aspergillosis - p. iii 155. Chapter 149: Current Drug Treatments for Allergy - p. iii 156. Chapter 150: Immunotherapy for Allergy - p. iii 157. Chapter 151: COPD Genetics - p. iii 158. Chapter 152: COPD Epidemiology - p. iii 159. Chapter 153: Epigenetics in COPD: An Epidemiological Point of View - p. iii 160. Chapter 154: Pathology of Chronic Obstructive Pulmonary Disease - p. iii 161. Chapter 155: Inflammatory and Immune Mechanisms in COPD - p. iii 162. Chapter 156: Biomarkers in COPD - p. iii 163. Chapter 157: Bacterial Colonization in COPD - p. iii 164. Chapter 158: Accelerated Lung Aging and Cellular Senescence in COPD - p. iii 165. Chapter 159: Mucus Hypersecretion, Hyperconcentration and Chronic Bronchitis - p. iii 166. Chapter 160: Trajectories of COPD - p. iii 167. Chapter 161: Clinical Features and Diagnosis of COPD - p. iii 168. Chapter 162: Overview of Current Management of COPD - p. iii 169. Chapter 163: Oxygen Therapy in COPD - p. iii 170. Chapter 164: Pulmonary Rehabilitation for COPD - p. iii 171. Chapter 165: Comorbidities in Patients With Chronic Obstructive Pulmonary Disease - p. iii 172. Chapter 166: Alpha 1 Antitrypsin - p. iii 173. Chapter 167: COPD in Never Smokers - p. iii 174. Chapter 168: Asthma—COPD Overlap - p. iii 175. Chapter 169: Bronchodilators for Airway Disease - p. iii 176. Chapter 170: Other Drugs for Asthma and COPD - p. iii 177. Chapter 171: New Drugs for Airway Diseases - p. iii 178. Chapter 172: Inhaler Devices - p. iii 179. Volume 3 - p. iii 180. Chapter 173: General Principles of ILD: Diagnosis and Management - p. iii 181. Chapter 174: The Physiology of Interstitial Lung Disease - p. iii 182. Chapter 175: Overview on Radiologic Patterns in Interstitial Lung Disease - p. iii 183. Chapter 176: Overview of the Histologic Patterns in Interstitial Lung Disease - p. iii 184. Chapter 177: The Role of Bronchoscopy in Interstitial Lung Disease - p. iii 185. Chapter 178: Comprehensive Care of Interstitial Lung Disease - p. iii 186. Chapter 179: Common Co-Morbidities in Fibrosing Interstitial Lung Disease - p. iii 187. Chapter 180: Interstitial Lung Abnormalities and Early Interstitial Lung Disease - p. iii 188. Chapter 181: The Genetics of Interstitial Lung Diseases - p. iii 189. Chapter 182: Interaction Between Epithelial and Mesenchymal Cells in Interstitial Lung Disease - p. iii 190. Chapter 183: The Extracellular Matrix-Cell Interaction in ILD - p. iii 191. Chapter 184: The Role of the Innate Immune System in Interstitial Lung Disease - p. iii 192. Chapter 185: Adaptive Immunity in Interstitial Lung Disease - p. iii 193. Chapter 186: Stem Cells and Progenitor Cells in Interstitial Lung Disease - p. iii 194. Chapter 187: Animal Models of Fibrotic Interstitial Lung Disease - p. iii 195. Chapter 188: Novel Approaches to Drug Discovery in Interstitial Lung Disease - p. iii 196. Chapter 189: Epidemiology and Diagnosis of Idiopathic Pulmonary Fibrosis - p. iii 197. Chapter 190: Acute Exacerbation of Idiopathic Pulmonary Fibrosis - p. iii 198. Chapter 191: Idiopathic Pulmonary Fibrosis-Treatment and Management - p. iii 199. Chapter 192: Organizing Pneumonia - p. iii 200. Chapter 193: Smoking-Related—Interstitial Lung Disease - p. iii 201. Chapter 194: Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease - p. iii 202. Chapter 195: Hypersensitivity Pneumonitis - p. iii 203. Chapter 196: Connective Tissue Diseases-Associated Interstitial Lung Disease: A Focused Study on Sjogren’s Syndrome, Mixed Connective Tissue Disease, and Systemic Lupus Erythematosus - p. iii 204. Chapter 197: Interstitial Pneumonia With Autoimmune Features - p. iii 205. Chapter 198: Rheumatoid Arthritis Interstitial Lung Disease - p. iii 206. Chapter 199: Scleroderma Associated Interstitial Lung Disease - p. iii 207. Chapter 200: Myositis-Associated Interstitial Lung Disease - p. iii 208. Chapter 201: Vasculitis and Alveolar Hemorrhage - p. iii 209. Chapter 202: Drug Toxicity and Interstitial Lung Disease - p. iii 210. Chapter 203: Occupational Interstitial Lung Disease - p. iii 211. Chapter 204: Sarcoidosis - p. iii 212. Chapter 205: Eosinophilic Interstitial Pneumonia - p. iii 213. Chapter 206: Lymphangioleiomyomatosis - p. iii 214. Chapter 207: Pulmonary Alveolar Proteinosis - p. iii 215. Chapter 208: Miscellaneous Interstitial Lung Diseases - p. iii 216. Chapter 209: Physiology of the Normal Pulmonary Circulation - p. iii 217. Chapter 210: Physiology of the Normal Right Ventricle - p. iii 218. Chapter 211: Pathology of Pulmonary Arterial Hypertension - p. iii 219. Chapter 212: Pathobiology of Pulmonary Hypertension - p. iii 220. Chapter 213: Pathobiology of Right Ventricular Failure - p. iii 221. Chapter 214: Clinical Features of Pulmonary Hypertension and Right Heart Failure - p. iii 222. Chapter 215: Classification of Pulmonary Vascular Disease - p. iii 223. Chapter 216: Imaging of the Heart and the Pulmonary Circulation in Pulmonary Hypertension - p. iii 224. Chapter 217: Cardiopulmonary Exercise Testing in Pulmonary Vascular Disease - p. iii 225. Chapter 218: Biomarkers in Pulmonary Hypertension - p. iii 226. Chapter 219: Cardiac Catheterization in Pulmonary Hypertension - p. iii 227. Chapter 220: Group 1 Clinical Features and Treatment - p. iii 228. Chapter 221: Exercise Training in Pulmonary Hypertension - p. iii 229. Chapter 222: Lung Transplantation for Pulmonary Arterial Hypertension: Recent Developments—Donor Organ Preservation, Bio-Artificial Lung and Xenotransplantation - p. iii 230. Chapter 223: Group 2 Pulmonary Hypertension: Clinical Features and Treatment - p. iii 231. Chapter 224: Group 3 PH: Clinical Features and Treatment - p. iii 232. Chapter 225: Group 4 PH—Chronic Thromboembolic Pulmonary Hypertension - p. iii 233. Chapter 226: Acute Pulmonary Embolism - p. iii 234. Chapter 227: Diseases Associated with Group 5 Pulmonary Hypertension - p. iii 235. Chapter 228: Pulmonary Hypertension in Children: A Global View - p. iii 236. Chapter 229: The Pulmonary Circulation and the Right Ventricle in ARDS - p. iii 237. Chapter 230: Hepatopulmonary Syndrome - p. iii 238. Chapter 231: Pulmonary Arteriovenous Malformations - p. iii 239. Volume 4 - p. iii 240. Chapter 232: Streptococcus pneumoniae - p. iii 241. Chapter 233: Pseudomonas aeruginosa - p. iii 242. Chapter 234: Mycoplasma and Chlamydophila - p. iii 243. Chapter 235: Legionella pneumophila - p. iii 244. Chapter 236: Aspergillus Lung Disease - p. iii 245. Chapter 237: Pneumocystis - p. iii 246. Chapter 238: Tuberculosis - p. iii 247. Chapter 239: Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) - p. iii 248. Chapter 240: Other Bacterial and Fungal Respiratory Bacterial Pathogens - p. iii 249. Chapter 241: Respiratory Viral Pathogens - p. iii 250. Chapter 242: Human Immunodeficiency Virus - p. iii 251. Chapter 243: Human Coronavirus Infections—Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and SARS-CoV-2 - p. iii 252. Chapter 244: Parasitic Infections of the Lung - p. iii 253. Chapter 245: The Respiratory Microbiome in Health and Disease - p. iii 254. Chapter 246: Pneumonia—Overview - p. iii 255. Chapter 247: Community-Acquired Pneumonia - p. iii 256. Chapter 248: Hospital-Acquired and Ventilator-Associated Pneumonia - p. iii 257. Chapter 249: Pneumonia in the Immunocompromised Host - p. iii 258. Chapter 250: Severe Acute Respiratory Syndrome Coronavirus 2 - p. iii 259. Chapter 251: Pleural Infection - p. iii 260. Chapter 252: Infective Exacerbations of Chronic Lung Disease - p. iii 261. Chapter 253: Bronchiectasis - p. iii 262. Chapter 254: Long Term Complications of Tuberculosis and Pneumonia - p. iii 263. Chapter 255: Antibiotic Therapy for Respiratory Infection - p. iii 264. Chapter 256: Environmental Influences on Respiratory Infection - p. iii 265. Chapter 257: Pleural Disease: Overview - p. iii 266. Chapter 258: Anatomy and Physiology of the Pleural Space - p. iii 267. Chapter 259: Imaging of the Pleura: Ultrasound - p. iii 268. Chapter 260: Imaging of the Pleura: CT, MRI and PET - p. iii 269. Chapter 261: Pleural Effusions: Overview and Diagnostic Approach - p. iii 270. Chapter 262: Pleural Effusion: Infection (Para-Pneumonic and Empyema) - p. iii 271. Chapter 263: Pleural Effusion: Malignancy - p. iii 272. Chapter 264: Pleural Effusion: Chylous Effusions - p. iii 273. Chapter 265: Eosinophilic Pleural Effusions - p. iii 274. Chapter 266: Pleural Effusion: Tuberculous Effusion - p. iii 275. Chapter 267: Pleural Effusion: Hepatic Hydrothorax - p. iii 276. Chapter 268: Pleural Effusion: Hemothorax - p. iii 277. Chapter 269: Pleural Effusions: Post-Surgical and Post-Cardiac Injury - p. iii 278. Chapter 270: Spontaneous Pneumothorax - p. iii 279. Chapter 271: Traumatic Pneumothorax - p. iii 280. Chapter 272: Pneumomediastinum - p. iii 281. Chapter 273: Bronchopleural Fistula Following Anatomical Lung Resection - p. iii 282. Chapter 274: Unexpandable Lung - p. iii 283. Chapter 275: Benign Pleural Thickening, Fibrosis and Plaques - p. iii 284. Chapter 276: Malignant Pleural Mesothelioma - p. iii 285. Chapter 277: Rare Pleural Diseases - p. iii 286. Chapter 278: Pleural Interventions - Thoracentesis - p. iii 287. Chapter 279: Pleural Interventions - Chest Drain Insertion - p. iii 288. Chapter 280: Pleural Interventions: Manometry - p. iii 289. Chapter 281: Pleural Interventions: Closed Pleural Biopsy - p. iii 290. Chapter 282: Pleural Interventions—Thoracoscopy - p. iii 291. Chapter 283: Pleurodesis - p. iii 292. Chapter 284: Indwelling Pleural Catheters - p. iii 293. Chapter 285: Overview of Lung Cancer - p. iii 294. Chapter 286: Lung Cancer Screening - p. iii 295. Chapter 287: Behavioral Science Behind Lung Cancer Screening - p. iii 296. Chapter 288: Epidemiology of Lung Cancer - p. iii 297. Chapter 289: Tobacco Dependency - p. iii 298. Chapter 290: Pulmonary Nodules - p. iii 299. Chapter 291: Preinvasive Airway Lesions - p. iii 300. Chapter 292: Clinical Presentation and Diagnostic Approach in Suspected Lung Cancer - p. iii 301. Chapter 293: The Role of a Lung CNS - p. iii 302. Chapter 294: Imaging Techniques in Lung Cancer - p. iii 303. Chapter 295: Differential Diagnosis of Mediastinal Masses - p. iii 304. Chapter 296: Endobronchial Ultrasound for Mediastinal Staging in Lung Cancer - p. iii 305. Chapter 297: Interventional Bronchoscopy - p. iii 306. Chapter 298: Pathology of Lung Cancer - p. iii 307. Chapter 299: Metastases From Lung Cancer - p. iii 308. Chapter 300: Management of Local Disease in NSCLC - p. iii 309. Chapter 301: Management of Locally Advanced Non-Small Cell Lung Cancer - p. iii 310. Volume 5 - p. iii 311. Chapter 302: Management of Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC) - p. iii 312. Chapter 303: Molecular Targetable Pathways – EGFR - p. iii 313. Chapter 304: Molecular Targetable Pathways—ALK - p. iii 314. Chapter 305: Molecular Targetable Pathways and Therapy—ROS1 - p. iii 315. Chapter 306: KRAS: The Art of Understanding a Complex Gene - p. iii 316. Chapter 307: Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras) - p. iii 317. Chapter 308: Current Role of Immunotherapy - p. iii 318. Chapter 309: Management of Advanced Disease in NSCLC - p. iii 319. Chapter 310: Symptomatic and Supportive Care - p. iii 320. Chapter 311: Pulmonary Complications of Lung Cancer Therapies - p. iii 321. Chapter 312: Small Cell Lung Cancer - p. iii 322. Chapter 313: Introduction and terminology of sleep disordered breathing - p. iii 323. Chapter 314: Physiology of Sleep From Infancy to Old Age - p. iii 324. Chapter 315: Obstructive Sleep Apnea Phenotyping to Understand Pathophysiology and Improve Treatment and Outcomes - p. iii 325. Chapter 316: Vascular Consequences of Obstructive Sleep Apnea - p. iii 326. Chapter 317: Metabolic Consequences of Obstructive Sleep Apnea - p. iii 327. Chapter 318: Cognitive and Neurologic Aspects of Obstructive Sleep Apnea - p. iii 328. Chapter 319: Clinical Assessment of the Patient With Respiratory Sleep Disorder - p. iii 329. Chapter 320: Role of Screening in Sleep Disordered Breathing (SDB) - p. iii 330. Chapter 321: Respiratory Polygraphy - p. iii 331. Chapter 322: Use of Polysomnography - p. iii 332. Chapter 323: Weight Loss and Positional Management in OSA - p. iii 333. Chapter 324: Positive Pressure Therapy in OSA - p. iii 334. Chapter 325: Role of Mandibular Advancement Splints and Dental Devices in OSA - p. iii 335. Chapter 326: ENT Management of Obstructive Sleep Apnea - p. iii 336. Chapter 327: Surgical and Anesthetic Assessment in Patients With SDB - p. iii 337. Chapter 328: Comorbidities and Their Impact on Sleep Disordered Breathing - p. iii 338. Chapter 329: Impact of Intrinsic Sleep Disorders on Sleep Disordered Breathing - p. iii 339. Chapter 330: Pathophysiology of Central Sleep Apnea and Complex Sleep Apnea Syndromes - p. iii 340. Chapter 331: Positive Airway Pressure Therapies in Central Sleep Apnea - p. iii 341. Chapter 332: Management of Complex Sleep Apnea Syndromes (Including Treatment Emergent and Treatment Persistent Central Sleep Apnea) - p. iii 342. Chapter 333: Pathophysiology of Obesity Hypoventilation Syndrome - p. iii 343. Chapter 334: Management of Obesity Hypoventilation Syndrome - p. iii 344. Chapter 335: Pathophysiology of Hypoventilation in Neurological, Neuromuscular and Chest Wall Disease - p. iii 345. Chapter 336: NIV in Ventilatory Failure Due to Neuromuscular and Chest Wall Disorders - p. iii 346. Chapter 337: Non-Invasive Ventilation in Acute, Post-Acute and Stable COPD - p. iii 347. Chapter 338: Medico Legal and Economic Aspects of OSA - p. iii 348. Chapter 339: Acute Respiratory Distress Syndrome - p. iii 349. Chapter 340: ARDS in Patients Without Risk Factors - p. iii 350. Chapter 341: Pulmonary Embolism Causing Severe Organ Failure - p. iii 351. Chapter 342: Life Threatening Asthma - p. iii 352. Chapter 343: Life Threatening Chronic Obstructive Pulmonary Disease (COPD) - p. iii 353. Chapter 344: Management of Acute on Chronic Respiratory Failure Associated With Interstitial Lung Disease - p. iii 354. Chapter 345: Severe Community-Acquired Pneumonia - p. iii 355. Chapter 346: Severe Hospital-Acquired Pneumonia - p. iii 356. Chapter 347: Management of Coronavirus Disease 2019 (COVID-19) Pneumonia - p. iii 357. Chapter 348: Challenges in Severe Influenza Pneumonia - p. iii 358. Chapter 349: Severe Middle East Respiratory Syndrome (MERS) Pneumonia - p. iii 359. Chapter 350: Herpesviruses in Critically Ill Patients With ARDS - p. iii 360. Chapter 351: Perioperative Management of Lung Transplant Recipients - p. iii 361. Chapter 352: Ventilator-Associated Lung Injury - p. iii 362. Chapter 353: Right-Ventricle Protective Ventilation - p. iii 363. Chapter 354: Optimizing Mechanical Ventilation in Refractory ARDS - p. iii 364. Chapter 355: Tracheostomy - p. iii 365. Chapter 356: When To Do a Tracheostomy? - p. iii 366. Chapter 357: Weaning From Mechanical Ventilation - p. iii 367. Chapter 358: Mechanical Ventilation in 2035: Indications, Monitoring and Outcomes - p. iii 368. Chapter 359: Optimizing Sedation in Patients Receiving Mechanical Ventilation - p. iii 369. Chapter 360: Dyspnea in Patients Receiving Mechanical Ventilation - p. iii 370. Chapter 361: ECLS: What Every Clinician Should Know - p. iii 371. Chapter 362: Cognitive Dysfunction in ARDS Survivors - p. iii 372. Chapter 363: Ventilator-Associated Events: Definitions and Uses - p. iii 373. Chapter 364: Ventilator-Associated Tracheobronchitis - p. iii 374. Chapter 365: Airways and Ventilation Management During CPR - p. iii 375. Chapter 366: The Obese Patient With Acute Respiratory Failure - p. iii 376. Chapter 367: Results of Mechanical Ventilation in Cancer Patients - p. iii 377. Chapter 368: Delirium in the Intensive Care Unit - p. iii 378. Chapter 369: Echocardiography of the Ventilated Patient - p. iii 379. Chapter 370: Donor Selection and Management - p. iii 380. Chapter 371: Organ Allocation - p. iii 381. Chapter 372: Lung Transplantation: Recipient Selection - p. iii 382. Chapter 373: Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant - p. iii 383. Chapter 374: Surgical Advances in Lung Transplantation - p. iii 384. Chapter 375: Lung Transplantation for Cystic Fibrosis - p. iii 385. Chapter 376: Lung Transplantation for Pulmonary Hypertension - p. iii 386. Chapter 377: A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis - p. iii 387. Chapter 378: Lung Transplantation for Chronic Obstructive Pulmonary Disease - p. iii 388. Chapter 379: Immunosuppression - p. iii 389. Chapter 380: Opportunistic Bacterial, Fungal and Viral Infections in Lung Transplantation - p. iii 390. Chapter 381: Lung Transplant Primary Graft Dysfunction - p. iii 391. Chapter 382: Acute Cellular Rejection - p. iii 392. Chapter 383: Antibody-Mediated Rejection After Lung Transplantation - p. iii 393. Chapter 384: Chronic Lung Allograft Dysfunction - p. iii 394. Chapter 385: Airway Complications After Lung Transplantation - p. iii 395. Chapter 386: Malignancy Following Lung Transplantation - p. iii 396. Chapter 387: Patient-Centered Outcomes in Lung Transplantation - p. iii 397. Volume 6 - p. iii 398. Chapter 388: Normal Lung Development in Relation to Clinical Practice and the Impact of Environment on Development - p. iii 399. Chapter 389: Structural Abnormalities at Birth (Haemangioma, TOF, Airway Malacia, CPM) - p. iii 400. Chapter 390: Prematurity and Intrauterine Insults - p. iii 401. Chapter 391: Measuring Respiratory Function - p. iii 402. Chapter 392: Imaging of the Lung in Childhood - p. iii 403. Chapter 393: Pathology of the Lung Through Childhood - p. iii 404. Chapter 394: Disorders of Respiratory Control in Childhood - p. iii 405. Chapter 395: Early Life Respiratory Infection - p. iii 406. Chapter 396: Community-Acquired Pneumonia in Childhood - p. iii 407. Chapter 397: Pleural Effusion, Necrotizing Pneumonia and Long-Term Morbidity of Respiratory Infection in Childhood - p. iii 408. Chapter 398: Cystic Fibrosis—Diagnosis, Genetics and Lifelong Effects - p. iii 409. Chapter 399: Cystic Fibrosis Cellular Treatments - p. iii 410. Chapter 400: Cystic Fibrosis Therapies - p. iii 411. Chapter 401: Primary Ciliary Dyskinesia - p. iii 412. Chapter 402: Bronchiectasis in Childhood (Including PBB) - p. iii 413. Chapter 403: Diffuse Parenchymal Lung Disease in Early Childhood - p. iii 414. Chapter 404: Diffuse Parenchymal Lung Disease in Later Childhood - p. iii 415. Chapter 405: Recurrent Wheeze of Early Childhood - p. iii 416. Chapter 406: Diagnosing, Monitoring and Treating Asthma - p. iii 417. Chapter 407: Severe Asthma in Children and Young People - p. iii 418. Chapter 408: Cardiac - Pulmonary Hypertension, Gastro-Intestinal (GOR, Hepatopulmonary Syndrome), Hematology/Oncology (Infections, Approach to Diagnosis), Neuromuscular (Bulbar, Diaphragm, Intercostal, Spinal) - p. iii 419. Chapter 409: Oxygen Therapy in Children - p. iii 420. Chapter 410: Long Term Ventilation in Children - p. iii 421. Chapter 411: Lung Transplantation in Children - p. iii 422. Chapter 412: Epidemiological Study Design - p. iii 423. Chapter 413: Indoor Environmental Allergens - p. iii 424. Chapter 414: Household Air Pollution and Associated Health Effects in Low and Middle Income Countries - p. iii 425. Chapter 415: Indoor Air Pollution in Industrialized Countries - p. iii 426. Chapter 416: Outdoor Allergens: Pollens and Molds and Their Relationship to Climate Changes - p. iii 427. Chapter 417: Air Pollutants Short-Term and Long Term Effects - p. iii 428. Chapter 418: Acute Inhalational Injury - p. iii 429. Chapter 419: Epidemiological Study of Respiratory Diseases Among Dust Exposed Workers - p. iii 430. Chapter 420: Desert Dust - p. iii 431. Chapter 421: Heavy Metals - p. iii 432. Chapter 422: Work-Related Asthma - p. iii 433. Chapter 423: COPD - p. iii 434. Chapter 424: Air Pollution in Interstitial Lung Diseases and Associated Autoimmune Diseases - p. iii 435. Chapter 425: Environment and Mesothelioma - p. iii 436. Chapter 426: Environmental Mycobacteria - p. iii 437. Chapter 427: Occupational and Environmental Tuberculosis - p. iii 438. Chapter 428: Respiratory Diseases in Farmers - p. iii 439. Chapter 429: Respiratory Health in Migrants and Refugees - p. iii 440. Chapter 430: Unraveling the Exposome in Direct and Indirect Respiratory Effects of Climate Change - p. iii 441. Chapter 431: Thunderstorm—Asthma: Thunderstorm and Asthma in Allergic-Atopic Subjects - p. iii 442. Index - p. iii 443. Authors - p. iii
